The platform

POLEX™ maps a drug's impact on the genome.

POLEX reads the tumour's DNA directly and shows two things: how unstable its genome is, and the impact a drug is having on it. This is read on the genome itself, not on gene transcription, using Oxford Nanopore sequencing and a trained neural network. The result shows whether a drug is acting on the tumour, before it goes near the patient.

How POLEX works

From a biopsy to a drug action report.

We grow the patient's own tumour as organoids on a plate, test treatments on them, and read the genome to see what actually works.

STEP 1

Take a biopsy

We start from the patient's own tumour, taken as a small biopsy.

STEP 2

Seed & grow organoids

Cells are seeded on a plate in our microfluidic system and grown into living, patient-derived organoids.

STEP 3

Test DNA-damaging drugs

DNA-damaging treatments are applied to the organoids, then read before and after.

STEP 4

Read on nanopore

Oxford Nanopore sequencing and a neural network read genetic instability across the genome.

STEP 5

Drug action report

An end-to-end report ranks the DNA-damaging treatment most likely to work.

Our own trained neural network turns the nanopore signal into a go / no-go call.

SIGNAL GO GO / NO-GO
POLEX · DRUG ACTION REPORT
✓ GO
Proceed to treatment
DNA-repair deficiency detected
DNA-damaging treatment, predicted response
PARP inhibitorBEST MATCH
87%
Platinum chemotherapy
64%
Radiotherapy
55%
Topoisomerase inhibitor
44%
Illustrative example. POLEX scores DNA-damaging therapies only, since it reads a drug's damage on the genome.

What POLEX measures

The impact on the genome, and whether the drug landed.

  • ✓ Measures both genetic instability and a drug's impact on the genome
  • ✓ Reads the DNA itself at single-base resolution, not gene transcription
  • ✓ Scores DNA-damaging therapies: PARP, platinum, radiotherapy and more
  • ✓ An end-to-end report to guide better clinical decisions